<div id="readability-page-1"><div><p>Celltrion, Inc. (KOSE:A068270) proposed to acquire Biopharmaceutical Manufacturing Facility in the United States from Eli Lilly and Company (NYSE : LLY) on July 29, 2025. Celltrion, Inc. signed an agreement to acquire Biopharmaceutical Manufacturing Facility in the United States from Eli Lilly and Company (NYSE : LLY) for $330 million on September 22, 2025. Celltrion, Inc. plans to invest 700 billion won (approximately $503 million) for the acquisition, with the possibility of an additional 300 billion won for small-scale or up to 700 billion won for large-scale expansion, depending on market demand. Celltrion, Inc. will conduct due diligence before deciding on the final agreement and aims to complete the deal within the year if finalized.</p><p>  The transaction is expected to close by the end of this year.</p><p>Celltrion, Inc. (KOSE:A068270) completed the acquisition of Biopharmaceutical Manufacturing Facility in the United States from Eli Lilly and Company (NYSE : LLY) on January 2, 2026.</p></div></div>

禮來

<p>Celltrion, Inc. 已簽署協議，以 3.3 億美元收購禮來公司在美國的一處生物製藥生產設施。該收購提議於 2025 年 7 月 29 日提出，涉及 7000 億韓元（約合 5.03 億美元）的投資，並可能根據市場需求進行額外投資。在最終確定協議之前，將進行盡職調查，預計交易將在 2025 年底完成。該收購於 2026 年 1 月 2 日完成</p>

Celltrion, Inc. 從禮來公司（NYSE：LLY）收購了美國的生物製藥製造設施